Nike wiped out $200B+ in market cap since November 2021. And the chart actually understates how bad it is.
This company made one bet that destroyed everything: the direct-to-consumer pivot. During COVID, Nike's online sales surged, and management convinced themselves the stay-at-home economy was permanent. They pulled product from Foot Locker, Dick's, and thousands of wholesale partners to push buyers through https://t.co/QAXD8gsLJf and Nike stores.
That ceded physical shelf space to On Running, Hoka, New Balance, and every competitor happy to fill the void. By the time Nike brought Elliott Hill in as CEO, customers had already moved on.
The China numbers are staggering. Seven straight quarters of declining revenue. Greater China sales dropped 17% last quarter. Next quarter Nike expects a 20% plunge. Meanwhile Lululemon is posting double-digit growth in the same market. Anta and Li-Ning are eating Nike's share from below. Nike's China revenue contribution fell from 18.6% in 2021 to 14.2% in 2025.
Yesterday Goldman Sachs, JPMorgan, and Bank of America all downgraded the stock on the same day. Net income fell 35% year over year. Gross margin has declined for seven consecutive quarters. And the stock still trades at 38x forward earnings, a premium over the S&P 500 average of 22x.
This is what a slow-motion brand collapse looks like with a luxury multiple attached to it. The turnaround keeps getting pushed further out. Management promised growth by early 2027. Wall Street priced that in. Now it's late 2027 at best.
The scariest part: Nike is still the #1 sportswear company by market cap. If this is what #1 looks like, the rest of the industry is running a different race entirely.
INSTEAD OF WATCHING NETFLIX TONIGHT.
Spend 1 hour with this.
Claude AI FULL COURSE that teaches you how to BUILD and AUTOMATE anything.
The people who watch this tonight will wake up tomorrow with a skill that most people will not have in 2 years.
The people who skip it will still be watching Netflix next year wondering why nothing in their life has changed.
Your call.
2. $IBRX at $7.13 - Biotech/Immunotherapy
ANKTIVA is the first FDA-approved immunotherapy for non-muscle invasive bladder cancer. Full-year 2025 revenue hit $113M, up 700% YoY. Q4 alone was $38.3M. Now approved in 33 countries. Expanding into lung cancer with a BLA filing targeted by Q4 2026. Randomized trial showed 84% complete response rate vs 52% for standard treatment. This is a real drug with real revenue in a space that desperately needs better options.
अशोक खरात ने तो पूरी की पूरी वेब सीरीज़ ही बना रखी है । खैर अब कोई ये नहीं कहेगा की पढ़े लिखे लोगो को झाँसे मे नही लाया जा सकता ।
जितनी भी महिलाओं के साथ अब तक का वीडियो बाहर आ रहा है सबके सब पढ़ी लिखी और अच्छे घर से लग रही हैं ।
#AshokKharat#Maharashtra#Ashok#webseries #BreakingNews
बाबा अशोक खैरात एक और वीडियो सामने आया है ये बहुत मजेदार।
#महाराष्ट्र पुणे के अंदर इस नालायक ने बड़ी चूदाई चलाई 😂😂
वाह रे बेंचोद सेक्स भी दिया ऑर पैसा भी 🤣
जीवन बहुत खूब सूरत मजा कर इया MC अशोक खैरात #viralvídeo#viral2025